Harnessing the unparalleled properties of human embryo stem cells (hESCs) for the therapeutic treatment of disease and injury will require a convergence of scientific developments with regulatory standards. In the case of the latter, it is especially critical that standards for clinically assisted reproduction be harmonized with those governing human cell and tissue transplantation, most notably with respect to procurement, donation, testing, processing, preservation, storage and distribution of cells. In the UK, existing infrastructure to address these considerations is undergoing extensive reorganization to keep pace with evolving European Union standards. The present best paradigm for defining standards for the therapeutic use of embryo-derived stem cells is experience with adult haematopoietic stem cells (HSC). However, compared with adult-derived stem cell, the origin of embryoderived stem cells from limiting quantities of tissue and their absolute dependence on in vitro culture to realise their therapeutic potential, makes optimization of their isolation and cultivation of even greater importance. Most notable is the requirement to create animal cell product-free culture environments to reduce the risk of cross-specific disease transmission. In the present paper, we review present and emerging standards in the isolation and banking of human embryo-derived stem cells for therapeutic use in the UK and international progress in the development of defined culture systems for this purpose.
Introduction
Stem cells (SCs) are primitive cells with a regulated capacity for self-renewal and multi-lineage proliferation and differentiation (Loeffler & Potten 1997) , precise control of which in vivo is essential for development and tissue renewal. In this context, the manipulation, isolation and transplantation of these cells or their derivatives is widely regarded as the next frontier in curative medicine. While stem cells can be sourced from a range of embryonic to adult tissues, it remains true that the proliferative and differentiative properties of this type of cell becomes increasingly restricted with tissue development, with practical consequences on their therapeutic utility in autologous (i.e. using one's own cells) or allogeneic (i.e. using donated cells) transplantation. Thus, although there will always likely be contexts where adult-derived cells provide the greatest therapeutic advantage for the treatment of a specific disease or injury, embryo-derived stem cells offer excellent long-term prospects for the development of curative therapies for a range of conditions, which presently cannot or are struggling to be met by transplantation of adult or fetal-derived tissues or alternative therapies. This includes nerve replacement or repair in spinal cord injury, provision of dopaminergic neurons for the treatment of Parkinson's disease and insulin-producing cells for the treatment of diabetes. These have been exemplified in animal models using mouse embryo stem cells or their derivatives (McDonald et al. 1999 , Lie et al. 2000 , Soria et al. 2000 , Bjorklund et al. 2002 . Similarly, there is now emerging evidence of benefit following transplantation of human embryonic stem cell derived neural progenitors and cardiomyocytes into animal models of Parkinson's disease and myocardial injury respectively (Ben-Hur et al. 2004 , Kofidis et al. 2006 .
Realizing therapeutic aspirations for human embryo stem cells (hESCs) requires convergence of the capacity to comply with existing and emerging standards for the transplantation of cells and tissues with the evolution of scientific and technical capability to preserve the properties of these cells whilst minimizing the risk of introducing unknown pathogens. Since the unique capacity of hESC for renewal and expansion offers realistic prospects for their broad usage, standards established for the procurement and processing of these cells today within individual nations should ideally be sufficiently comprehensive to accommodate their global acceptance and utility in the future. In this paper, our focus is on the progress of the UK to achieve the safe and quality-assured evaluation of hESCs in the clinic. Within this context, we discuss underpinning fundamental principles governing donation, procurement, testing, processing, preservation, storage and distribution of embryos and cells based on experience in adult cell and tissue transplantation and European Union (EU) Directives. Given the absolute dependence of hESCs on cell culture, we also address international progress in the creation of defined and animal cell product-free culture environments to isolate hESCs for cell banking. While definition and evolution of high-throughput systems for hESC expansion and differentiation are equally important to their ultimate therapeutic use, they are beyond the scope of this paper.
Existing and emerging EU/UK standards governing human cells and tissues
Globally there is widespread recognition of a need for an internationally unified framework to ensure high standards of quality and safety with respect to cell and tissue transplantation. Accordingly, in 2003, the World Health Organisation (WHO) acknowledged that the volume and complexity of activity in this arena needed to be taken into account by WHO guidelines (see report on access and safety in tissue and organ transplantation: WHO/HTP/EHT/ T-2003.1; online at http://www.who.int/ethics/topics/en/ madrid_report_final.pdf). Specifically, cited were: † Poor levels of education, training and research in tissue banking globally. † Inconsistent approaches to donor consent. † Limited or non-existent evidence for efficacy of transplantation of some tissues. † Unregulated commercialization. † Inability to provide 'origin to destiny' traceability of tissues. † Lack of harmonization of regulatory standards delivering high costs for tissue banks. † Concern about self-sustainability of 'not-for-profit banks', and excessive income of 'for profit banks' in the context of altruistically donated human material. To the credit of EU legislators and contributors involved in its drafting and consultation, Directive 2004/23/EC comprehensively identifies the multitude of factors that must be considered for quality-assured and safe therapies involving human cells. As summarized in Tables 1 and 2 , it specifies provisions to be addressed by multiple parties within member states from designated authorities to tissue facilities, third parties and individuals. It not only allows for member states to impose more restrictive measures but also promotes unification of standards that ultimately benefit all participants. The implications of these provisions are significant with increased burdens of responsibility and costs to the public and private sectors and end beneficiary awaiting new treatments. While it is easy to envisage that the therapeutic use of cells in general or with hESC derivatives in specific could be achieved more expediently without these standards, the consequences associated with inconclusive or adverse results that could occur without having them cannot be overlooked. This is borne out by recent experience with gene therapy trials, or transmission of infectious pathogens via blood products or tissues (Gode & Bhide 1988 , Simonds et al. 1992 , MacLaren et al. 2005 , Ludlam et al. 2006 . While some of the complications that have been experienced could arguably be described as unforeseen on the basis of available knowledge, this in itself does not substantiate less rigorous standards. Rather, it emphasizes the need for the forethought that such standards invoke. Table 2 .
UK road to hESC in therapy
Changes in EU and UK legislation have prompted restructuring of non-departmental regulatory bodies within the UK Department of Health, for purposes of harmonizing oversight of what previously were regarded as distinct domains encompassing assisted reproduction and transplantation. Since 1991, the Human Fertilisation and Embryology Authority (HFEA) has licensed and monitored UK clinics offering assisted conception, as well as all UK-based research into human embryos and storage of eggs, sperm and embryos. The HFEA has also had the duty to review all new developments in treatment and research, to engage in public debate and to advise ministers. By contrast, in 2001, the Medicines Control Agency acquired responsibility for accreditation of cell and tissue banks processing and storing human tissues for therapeutic use, and became the Medicines Healthcareproducts Regulatory Agency (MHRA). With effect from 7 April 2006, a new Department of Health body, the Human Tissue Authority (HTA) came into force. Together with the HFEA, it will serve as the competent authority for the EU Cells and Tissues Directives and the UK Human Tissue Act (2004) . The HTA will be responsible for licensing and regulating tissue establishments and the storage of human material for education, training and research and also anatomical and post-mortem examination. The guiding principles used for such activities will be defined by codes of practice. These will cover issues, such as consent, definition of death, control of existing holdings of human tissues, removal, import and export of human tissue and organs and storage of human tissue with the exception of gametes and embryos, which will remain regulated by the HFEA. According to the Secretary of Health's review of Department of Health's Arm's Length Regulatory Bodies (20 May 2004) the HTA and HFEA will be merged by 2008 to create a new authority, the Regulatory Authority for Tissues and Embryos (RATE).
HESC lines derived in the UK under licence from the HFEA must be deposited in the UK Stem Cell Bank (UKSCB), hosted at the National Institute for Biological Standards and Controls (NIBSC). Established in 2002, this government-backed facility was the first of its kind to be established with the aim of providing a quality-assured repository for hESCs for research and therapeutic purposes (Healy et al. 2005) . The bank was accredited by the MHRA in June 2004. At the time of writing, 24 lines had been approved for deposition in the bank, of which 5 had been deposited (Glyn Stacey, Personal Communication). Five of these had been derived in the UK. While at present all these lines are regarded as 'research grade' owing to the nature of facilities and procedures in place at the site and time of their derivation, multiple groups across the UK including ourselves are actively engaged in upgrading procedures and facilities designated for this purpose to fulfil existing and emerging regulatory standards for clinical use. International competition to attain these standards is intense, and recently one multinational effort led by the Singapore-based biotechnology company Embryo Stem Cell International, announced the derivation of two new hESC lines in facilities operating to present Good Manufacturing Practice (GMP) as defined in Singapore (for further information, see www.escellinternational.com/).
As embryologists and scientists unaccustomed to thinking in manufacturing terms, the learning curve has been steep. Key challenges have included: (1) the anticipation and implementation of elevated quality standards that are still being defined, (2) addressing the needs of transplantation medicine without compromising assisted reproduction services and (3) securing the necessary resources to achieve elevated standards for a therapeutic objective whose benefits remain speculative. The funding breach to support the latter remains an outstanding issue, with many efforts across the UK moving slowly forward with varied and piece-meal support from either the Medical Research Council, Charitable trusts, Universities and/or regional economic development agencies. Although private-public funding partnerships to support the general translation of stem cell research to the clinic have been discussed, this support has yet to be realized. Lessons from haematopoietic stem cell transplantation Current and emerging standards and perspectives on tissue and cell therapies as embodied in the EU directive have culminated from decades of experience in adult organ and tissue transplantation. Best practice which has developed from this experience is defined by standards established by the Joint Accrediation Committee for the International Society for Cellular Therapy (ISCT) and the European Group for Blood and Marrow Transplantation (EBMT), or JACIE (http://www.jacie.org). Arguably, the best present example for the use of cells in therapy is the use of haematopoietic stem cells (HSC) and progenitors for the treatment of blood cell diseases, such as acute and chronic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, severe aplastic anaemia and systemic autoimmune disease (e.g. severe rheumatoid arthritis or systemic lupus erythematosus). It is important to note that these treatments have largely relied on primary cell preparations and are not involved in the type of extensive cell culture that hESCs will ultimately invoke. However, this experience is valuable for interpreting and anticipating emerging standards, as noted below.
Donor consent, selection and screening
While the original scope of UK Human Fertilisation and Embryology Act (1990) and resulting HFEA code of practice addressed patient consent for the use of gametes and embryos in IVF treatment, storage by cryopreservation, disposal and the licensing of research in human reproduction and development, the production of a tangible asset such as stem cells has raised new issues in the consenting process, the impact of which are still being addressed. Based on experience with consenting for blood products, including HSCs, there is now a greater recognition for a need to provide information and obtain instruction regarding disposal of tissues, their commercial exploitation and feedback of information relevant to the health status of the donor. As noted in the first EU Cells and Tissues technical annex (summarized in Table 2 ), more rigorous selection and microbiological screening of gamete donors is required, consistent with the present requirements of the UK Blood Services & NIBSC Guidelines for the Blood Transfusion Services (the Red Book). Donors will be required to complete a health and medical history questionnaire. Furthermore, on the basis of family history, the donor's first degree relatives may have to be free of non-trivial autosomal dominant or X-linked disorders with age of onset extending beyond the age of the donor (such as Huntingdon's chorea), autosomal dominant disorders with reduced penetrance (such as Marfan's syndrome or Alport's disease) and autosomal recessive disorders with high prevalence in the general population (such as cystic fibrosis, Factor V Leiden and haemochromatosis). A family history of familial disease with a major genetic component (such as cleft lip, spina bifida or congenital malformation), non-trivial Mendelian disorder (such as haemophilia, hereditary hypercholesterolaemia or neurofibromatosis), familial disease with a reliably indicated major genetic component (such as juvenile diabetes mellitus, severe hypertension or rheumatoid arthritis) or of chromosomal rearrangement may also preclude contribution to therapeutic grade cell lines. Consideration will also need to be given as to the extent to which the potential for later development of disease in donors of embryos might impact upon the clinical safety or utility of a cellular therapeutic product. The significance of this point is underscored by stipulations in the EU cells and tissues directive for maintenance of full traceability of tissues from donor(s) to recipient patient(s) for at least 30 years following the last clinical use of any therapeutic product derived from those cells.
In recognition of the need to improve and consolidate provision of information to assisted conception patients and consenting for embryo donation for stem cell research, the MRC has funded the co-ordination of this effort across multiple centres. This has resulted in the formation of the human Embryonic Stem Cell Co-ordinators group (hESCCO; http://ukstemcell.net). Till date, this group has worked to standardize donor information and consent forms and the consenting process in accordance with HFEA guidelines, and establish a secure database to provide solid evidence of public confidence in embryo donation for stem cell research, the latter in concert with social scientists.
With publication of EU directive 2006/17/EC, there is now more clarity on microbiological testing that is required of donors of cells or tissues (summarized in Table 2 ). With the exception of additional testing dependent on the donor's travel and exposure history, it is assuring that the present screening of third party donors of gametes for assisted reproduction of an infertile woman is consistent with these requirements. However, one nuance is an EU requirement for testing at the time of donation. In the context of embryo donation for stem cell research, this could be interpreted to imply repeat blood sampling of donors of the gametes resulting in that embryo closer to the time the embryos are created.
Facilities specification and operation
Considerable attention and concern has focused on the necessity to handle gametes and embryos in an in vitro fertilization clinical setting in the same manner as cells and tissues for transplantation. Most notable have been fears of incorporating provisions for the specification and operation of clean rooms described by EC Guide to GMP as contained in Rules and Guidance Table 1 ). Recognition of the importance of quality systems in assisted reproduction treatment in Europe is not new, but until recently has been implemented entirely voluntarily (Wikland & Sjoblom 2000) . Irrespective of lab specification, it is clear that settings supporting IVF and hESC derivation will require quality systems comparable with those required by the MHRA for tissue establishments. This will entail a fully audited quality management system, such as the ISO9000 system (http://www.iso.org/iso/en/iso9000-14000/index.html) or other systems meeting the requirements of the HTA. These would feature: † Pre-commissioning validation and regular monitoring of equipment and facility performance. † Validation and review of all measurable processing parameters against defined specifications. † An extensive documentation system covering management policies, staff training, operating procedures and records. † Formal contracts with all third party suppliers of materials and services.
Based on the experience provided by the qualityassured production of blood cells and products, a number of other considerations are worth noting. These include: † Failsafe and backup systems for critical equipment and storage. † Data registry encompassing consent/authorization; donor history, examination and testing; and record of procurement. This would be fully auditable and password-protected in compliance with the Data Protection Act. † Electronic systems to uniquely code and track each cell line. These should have inbuilt access controlled safety features, which would preclude inappropriate release of cells for clinical purposes e.g. if cell lines are bacteriologically contaminated, the viral markers from the original donors are reactive, the medical history is not acceptable, etc.
Evaluation of hESCs in clinical trials
Although the clinical evaluation of hESCs may be a few years away, future-proofing present standards is necessary. Many of the same factors will need to be defined and optimized as presently met by transplantation of fetal and adult cells and tissues. This includes definition of the optimum cell lineage for transplantation, the route and timing of administration, 'dosage' of cells and whether single or multiple administrations are required, definition of clinical subsets of disease, interplay of other medications, etc. Appropriate investigatory and clinical end points need to be defined, as well as the necessity and ethical appropriateness of randomizing or blinding the study (Cesaro 2004 , Dunnett & Rosner 2004 . The extensive dependence of hESCs on culture systems to expand and differentiate them, presently achieved by reliance on research grade or animal sourced reagents, arguably makes this a greater issue for the therapeutic use of these cells than for cells sourced from other tissues. Reagents need to be quality assured and traceable, and exposure to animal cell products could theoretically brand a stem cell product as a xenobiotic, impacting on the patient follow-up in a clinical trials. At present, clinical trials of experimental therapeutics need to be carried out in compliance with: (1) the EU Directive on clinical trials (2001/20/EC) and (2) the Research Governance Framework for Health and Community Care. These cover the responsibilities of the Sponsor, approval of the trial by the relevant competent authority (MHRA) and Ethics Committee(s) and the conduct of the study according to the principles of Good Clinical Practice. In addition, any clinical trial must be reviewed and monitored by an independent trial monitoring committee. Any experimental therapeutic product would be manufactured in compliance with GMP standards and systems would need to be in place for the recording and investigation of any adverse events occurring during the study and ongoing pharmacovigilance. Written informed consent would be obtained for all participants before commencement on the study and specific documented procedures would be in place for the handling of donor and patient trial samples and archive material. Patient and donor related data would be handled in accordance with the Data Protection Act 1998 and strict confidentiality would be maintained. The issue of compensation in the event of non-negligent harm would be addressed in line with Ethics Committee requirements and appropriate indemnity established.
Evolution of defined culture systems supporting hESC isolation
Whilst the emphasis of existing and emerging regulatory standards is on quality assurance and traceability of all donations and procedures, a critical parameter in optimizing the safety of hESCs for therapy is improvement of the culture systems supporting them. Ultimately, these systems need to produce sufficient quantities of functionally normal cells that are tolerable, or can be made tolerable to the recipient. Cells produced by these systems also need to be free of, or have minimal risk of contaminants that could harm the individual, or result in the transmission of disease to the general population. A significant concern for the latter is the potential for crossspecific or zoonotic transmission of unknown pathogens associated with exposure of cells in culture to animal tissues or undefined tissue products. Historically, zoonoses have accounted for some of the most virulent diseases known to man, including anthrax, hantavirus, Q-fever, and more recently variant Creutzfeldt-Jakob disease (CJD) arising from bovine spongioform encephalopathy (Weiss 2003 , Parker et al. 2006 . Thus a critical first step for the communal safety of stem cell technology is the evolution of completely humanized and animal product-free culture systems.
Eight years on from the first successful hESC derivation by Thomson et al. (1998) all successful efforts to isolate and expand these cells have continued to involve direct exposure to one or more undefined animal sourced blood or cell products. This includes the use of blood complement to 'immunosurgically' lyse blastocyst outer trophectodermal cells in order to recover embryo inner cell mass (ICM), mitotically inactivated mouse embryo fibroblasts (MEF) or MEF-derived extracts for embryo cell attachment and outgrowth, and supplementation of media with bovine serum or serum-derived products (Reubinoff et al. 2000 , Lanzendorf et al. 2001 , Hovatta et al. 2003 , Mitalipova et al. 2003 , Cowan et al. 2004 , Heins et al. 2004 , Klimanskaya et al. 2005 , Ludwig et al. 2006 . However, many studies have demonstrated the capacity to obviate direct exposure to one or more of these factors. Thus, at least two groups demonstrated hESC derivation from whole embryos without animal immune complement to isolate ICM (Heins et al. 2004 , Simon et al. 2005 . In place of MEFs, human fibroblasts derived from neonatal foreskin and adult placentas have also been exemplified to serve as feeders for the outgrowth of embryo ICM and whole blastocysts respectively (Hovatta et al. 2003 , Simon et al. 2005 . The prospect of feeder-free isolation has also been exemplified by growth of embryo ICM on extracellular matrix (ECM) extracted from MEFs (Klimanskaya et al. 2005) and most recently on a combined preparation of human sourced collagen IV, fibronectin, laminin and vitronectin (Ludwig et al. 2006) . In our own recent efforts, we have isolated six new hESC lines from whole blastocysts, without exposure to animal immune complement, on an ECM substrate of purified human laminin and transitional reliance on mitotically inactivated human fibroblast feeder cells. Most notably, one of these lines was isolated using a serum-free medium (SFM) containing only human sourced and recombinant proteins (De Sousa et al. 2005 , Fletcher et al. 2006 . To our knowledge, this is the first exemplification of a new hESC line derived without direct exposure to any animal cell product, and as such represents another significant sequential step in the generation of conditions suitable for the derivation of therapeutic grade stem cells with reduced risk for transmitting zoonotic pathogens.
In the absence of a detailed understanding of cellculture requirements, serum, normally of bovine origin, is a common media supplement. It provides a range of growth factors capable of stimulating both growth and differentiation and is a valuable nutritional source of protein such as albumin, which has the added side benefit of facilitating cell attachment to substrates. Accordingly, almost all efforts to derive hESC till date have involved supplementation of minimal essential medium with bovine-sourced serum (Thomson et al. 1998 , Reubinoff et al. 2000 , Lanzendorf et al. 2001 , Hovatta et al. 2003 , Mitalipova et al. 2003 , Pickering 2003 , Stojkovic et al. 2004 or bovine serum replacement (bSR; marketed as KNOCKOUT SR, Invitrogen) (Cowan et al. 2004 , De Sousa et al. 2005 , Klimanskaya et al. 2005 , Simon et al. 2005 , of which albumin is a major component (Price et al. 1998) . The SFM used in our own recent work was based on X vivo 10 (Cambrex, Wokingham Berkshire, UK), a product marketed for human therapeutic applications involving haematopoietic cells, to which basic Fibroblast Growth Factor (bFGF) alone was added (De Sousa et al. 2005 , Fletcher et al. 2006 . This was based on its capacity to support hESC self-renewal in SFM as well as bSR supplemented media under feeder-free culture conditions (Xu et al. 2001 . Although the base composition of this media is proprietary, human insulin, transferrin and albumin are specified in available product information. Recently, Ludwig et al. (2006) published details of their own animal protein-free media supporting hESC derivation. In addition to containing a broad range of inorganic salts, trace minerals, energy substrates, lipids, amino acids and vitamins, this media contains a number of human growth factors and proteins, including bFGF, TGF-b1, GABA, pipecolic acid, glutathione, insulin, transferrin and albumin. Previous studies developing feeder-free culture environments to support established hESC lines have suggested that TGFb1 and leukaemia inhibitory factor (LIF), and the bone morphogenetic protein (BMP) antagonist Noggin, synergize with bFGF to suppress differentiation and sustain self-renewal in non-conditioned medium supplemented with bSR (Amit et al. 2004 , Xu et al. 2005 . How universal variations in culture environment and handling are for deriving and sustaining hESC lines remains to be formally evaluated and could be dependent on genetic or epigenetic heterogeneity in the cell lines themselves. Another issue affecting the derivation and expansion of undifferentiated hESCs appears to be the requirement to maintain cell association during passaging. This is reflected initially by a requirement for manual dissection and freezing of cells at high density in order to ensure recovery of cells post-thawing. This is further reflected by poor cloning efficiencies of less than 1% of established lines on or off of feeders (Amit et al. 2000 (Amit et al. , 2004 . While our and others recent success (Fletcher et al. 2006 , Ludwig et al. 2006 in isolating hESCs in media containing only human-sourced recombinant and purified proteins is significant, indirect exposure to animalsourced tissues used in reagent preparation remains an outstanding safety issue for therapeutic objectives. An example of this is the fact that culture of human fibroblast feeders still normally involves exposure to Low Serum Growth Supplement (LSGS; Cambrex, Berkshire, UK) containing 2% (v/v) fetal bovine serum. Fortunately, this serum is sourced from transmissible spongioform encephalopathy (TSE)-free herds in New Zealand that have been certified by the MHRA and comparable health agencies through the world. However, there is of course no guarantee that this source does not carry other unknown pathogens. Similarly, procedures used by manufacturers in the purification of human proteins such as albumin or ECM proteins from tissues undoubtedly still utilize animal-sourced reagents (i.e. trypsin or collagenase), since these are the most commonly available to manufacturers of research grade material. The future production of therapeutic grade stem cells will thus necessitate reliance on therapeutic grade reagents, whose production may in turn necessitate implementing novel strategies for organic synthesis of molecules or the use of recombinant gene technology in evolutionarily distant species (i.e. plant and insect).
A perception of a prevalence of TSE in the UK in the form of CJD has been an issue which has resulted in US bans on the therapeutic use of blood cell products derived from prospective donors that have resided or been transfused in the UK (i.e. http://www.fda.gov.cber/gdlns/cjdvcjd/pdf). This has the potential to impact on the worldwide acceptance of UK-derived hESCs irrespective of their compliance with emerging UK and EU standards. However, according to recent WHO guidelines on Tissue Infectivity Distribution in transmissible spongioform encephalopathies (September 2005) , no detectable TSE infectivity has been reported in reproductive tissues such as testis, prostate, semen, ovary, uterus, placental fluids, fetuses and embryos (http//www.who.int/blood products/tse/WHO%20TSE%20Guidelines%20FINAL-22%20JuneupdatedNL.pdf). Thus, while this remains the case, there is no rationale for discriminating against UK-derived hESCs or products providing that any human or animal serum or serum products used in their culture are obtained from TSE-low risk or free sources.
Conclusion
To date, no human embryonic stem cell line has been derived in the UK that fulfils existing and emerging quality assurance requirements stipulated by EU directives and UK legislation. However, it is apparent that significant progress is being made on this objective across all fronts. Clarity on the regulatory requirements is gradually emerging with opportunities to anticipate undefined specifications existing provided that adequate resources are available to address physical and quality assurance requirements. Taking as a whole, UK efforts to update its regulatory oversight of cells and tissue transplantation, and the support that exists for the establishment and co-ordination of stem cell research, banking and clinical use, it is reasonable to conclude that the UK remains globally competitive to achieve therapeutic objectives. A fundamental distinction between the prospective therapeutic use of hESCs and present transplantation of adult cells and tissues is the absolute requirement of the former for quality-assured cell culture methodology. Although it is not essential that the first hESC lines produced in quality-assured facilities be isolated in animal cell product free conditions, recent progress, for example, by Ludwig et al. 2006 makes it conceivable that no direct exposure can be guaranteed. However, it may be sometime before all of the necessary therapeutic-grade reagents are available to eliminate the possibility of indirect exposure to animal sources of unknown pathogens.
